Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome

Y Lee, N Kamada, JJ Moon - Advanced drug delivery reviews, 2021 - Elsevier
The gastrointestinal tract (GIT) affects not only local diseases in the GIT but also various
systemic diseases. Factors that can affect the health and disease of both GIT and the human …

The dual role of neutrophils in inflammatory bowel diseases

O Wéra, P Lancellotti, C Oury - Journal of clinical medicine, 2016 - mdpi.com
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are
characterised by aberrant immunological responses leading to chronic inflammation without …

Цитокины в патогенезе и лечении заболеваний человека

АС Симбирцев - 2018 - elibrary.ru
В монографии приведены сведения по роли цитокинов в регуляции физиологических
процессов, защитных реакций организма и в патогенезе иммунопатологических …

The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease

G Holleran, L Lopetuso, V Petito, C Graziani… - International journal of …, 2017 - mdpi.com
Inflammatory bowel disease (IBD) is an immune-mediated inflammatory condition causing
inflammation of gastrointestinal and systemic cells, with an increasing prevalence …

Recent trends in pharmacological activity of alkaloids in animal colitis: potential use for inflammatory bowel disease

AC Alves de Almeida, FM de-Faria… - Evidence‐Based …, 2017 - Wiley Online Library
Inflammatory bowel disease (IBD) is a chronic and disrupted inflammation of the
gastrointestinal tract. IBD have two main conditions, Crohn's disease and ulcerative colitis …

Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center …

PS Dulai, JC Buckey Jr, LE Raffals… - Official journal of the …, 2018 - journals.lww.com
BACKGROUND: Hyperbaric oxygen therapy (HBOT) markedly increases tissue oxygen
delivery. Case series suggest it may have a potential therapeutic benefit in ulcerative colitis …

Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond

A Di Paolo, G Luci - Frontiers in Pharmacology, 2021 - frontiersin.org
The pharmacotherapy of inflammatory bowel diseases (Crohn's disease and ulcerative
colitis) has experienced significant progress with the advent of monoclonal antibodies …

Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis

CV Almario, MS Keller, M Chen, K Lasch… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Recent drug approvals have increased the availability of biologic therapies
for inflammatory bowel disease (IBD), making it difficult for patients with ulcerative colitis …

[HTML][HTML] Modern drug discovery for inflammatory bowel disease: The role of computational methods

TO Johnson, AO Akinsanmi, SA Ejembi… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Inflammatory bowel diseases (IBDs) comprising ulcerative colitis, Crohn's disease and
microscopic colitis are characterized by chronic inflammation of the gastrointestinal tract. IBD …

The Benefits of In Silico Modeling to Identify Possible Small-Molecule Drugs and Their Off-Target Interactions

M Zloh, SB Kirton - Future medicinal chemistry, 2018 - Taylor & Francis
The research into the use of small molecules as drugs continues to be a key driver in the
development of molecular databases, computer-aided drug design software and …